Cargando…

Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens

OBJECTIVES: The objective of this study was to describe the real-world use and effectiveness of dolutegravir-based regimens (DBRs) in routine clinical practice in the United Kingdom. METHODS: Retrospective analysis was conducted using data from four National Health Service trusts using Climate-HIV,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okoli, Chinyere, Schwenk, Achim, Radford, Matthew, Myland, Melissa, Taylor, Stephen, Barnes, Justine, Fox, Ashini, Darley, Alison, Grimson, Fiona, Reeves, Iain, Munshi, Sajid, Croucher, Adam, Boxall, Naomi, Paice, Alistair, van Wyk, Jean, Benn, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593281/ https://www.ncbi.nlm.nih.gov/pubmed/34156330 http://dx.doi.org/10.1177/09564624211027099

Ejemplares similares

Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database
por: Okoli, C, et al.
Publicado: (2020)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
por: Evitt, Lee A., et al.
Publicado: (2023)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
por: Taha, Huda, et al.
Publicado: (2015)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence
por: Punekar, Y S, et al.
Publicado: (2021)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

HIV–1 resistance to dolutegravir: update and new insights
por: Wainberg, Mark A, et al.
Publicado: (2015)

Switch to dolutegravir is well tolerated in Thais with HIV infection
por: Goh, Orlanda Q, et al.
Publicado: (2019)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Dolutegravir Resistance in Malawi’s National HIV Treatment Program
por: van Oosterhout, Joep J, et al.
Publicado: (2022)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
por: Kandel, Christopher E, et al.
Publicado: (2015)

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
por: Zhang, Jianping, et al.
Publicado: (2015)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Willingness to pay for antiretroviral drugs among HIV and AIDS clients in south‐east Nigeria
por: Mbachu, Chinyere, et al.
Publicado: (2017)

Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
por: Saborido-Alconchel, Abraham, et al.
Publicado: (2023)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini
por: Duga, Alemayehu L., et al.
Publicado: (2022)

Effect of Dolutegravir and Multimonth Dispensing on Viral Suppression Among Children With HIV
por: Mugo, Cyrus, et al.
Publicado: (2023)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection
por: Cahn, Pedro, et al.
Publicado: (2022)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
por: Pialoux, Gilles, et al.
Publicado: (2015)

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review
por: Hill, Andrew, et al.
Publicado: (2018)

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
por: Giacomelli, Andrea, et al.
Publicado: (2020)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
por: Punekar, Yogesh Suresh, et al.
Publicado: (2019)

Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
por: Van de Wijer, Lisa, et al.
Publicado: (2021)

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
por: Mondleki, Enkosi, et al.
Publicado: (2022)

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023)

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
por: Liu, Huanxia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0csf377iqn7secvm7v7nvgv1gp